Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project)

Biomedicine and Pharmacotherapy

Volumn 67, Issue 4, 2013, Pages 293-298

  Menzaghi, Barbara ^a   Ricci, Elena ^b   Carenzi, Laura ^b   Parruti, Giustino ^c   Orofino, Giancarlo ^d   Guastavigna, Marta ^d   Madeddu, Giordano ^e   Maggi, Paolo ^f   Di Biagio, Antonio ^g   Corsi, Paola ^h   Penco, Giovanni ⁱ   De Socio, Giuseppe ^j   Martinelli, Canio ^h   Vichi, Francesca ^k   Celesia, Benedetto Maurizio ^l   Franzetti, Marco ^b   Grosso, Carmela ^m   Molteni, Chiara ⁿ   Bonfanti, Paolo ⁿ   Quirino, Tiziana ^a  

^a BUSTO ARSIZIO HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Pescara Hospital   (Italy)

^d AMEDEO DI SAVOIA HOSPITAL   (Italy)

^e UNIVERSITY OF SASSARI   (Italy)

^f UNIVERSITY OF BARI   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

^h CAREGGI UNIVERSITY HOSPITAL   (Italy)

ⁱ GALLIERA HOSPITAL   (Italy)

^j SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^k SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^l GARIBALDI HOSPITAL   (Italy)

^m Cesena Hospital   (Italy)

ⁿ A MANZONI HOSPITAL   (Italy)

more..

Author keywords

Antiretroviral therapy; Darunavir; HIV; Protease inhibitors; Safety

Indexed keywords

ALANINE AMINOTRANSFERASE; DARUNAVIR PLUS RITONAVIR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASTHENIA; CD4 LYMPHOCYTE COUNT; CLINICAL PRACTICE; CONFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEPATITIS C; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; LIPID METABOLISM; LIVER FAILURE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTICENTER STUDY; MUSCLE WEAKNESS; PAIN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PRURITUS; SEIZURE; SIDE EFFECT; SPINE FRACTURE; SURVIVAL RATE; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

ADULT; AGE FACTORS; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INTERNET; ITALY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RITONAVIR; SULFONAMIDES; SURVIVAL ANALYSIS; TIME FACTORS; VIRAL LOAD;

EID: 84876891962     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2012.12.005     Document Type: Article

References (15)

1. Stone V.E. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clin Infect Dis 2001, 33(6):865-872.
2. Scott J.D. Simplifying the treatment of HIV infection with ritonavir-boosted protease inhibitors in antiretroviral-experienced patients. Am J Health Syst Pharm 2005, 62(8):809-815.
3. Friis-Møller N. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007, 356:1723-1735. The DAD Study Group.
4. Rachlis A., Clotet B. Safety, tolerability and efficacy of Darunavir (TMC114) with low-doses Ritonavir in treatment-experienced, hepatitis B or C co-infected patients in Power 1 and 3. HIV Clin Trials 2007, 8(4):213-220.
5. De Socio G.V., Bonfanti P. Cholesterol levels in HIV-HCV infected patients treated with lopinavir/r: results from the SCOLTA project. Biomed Pharmacother 2008, 62(1):16-20. CISAI Study Group.
6. Shen L., Peterson S. Dose-response curve slope set class-specific limits on inhibitory potential of anti-HIV drugs. NatMed 2008, 14:762-766.
7. Boffito M., Miralles D. Pharmacokinetics, efficacy and safety of darunavir/ritonavir 800/100mg once-daily in treatment-naïve and experienced patients. HIV Clin Trials 2008, 9:418-427.
8. Mills A., Nelson M. Once-daily darunavir/ritonavir vs lopinavir-ritonavir in treatment-naïve. HIV-1 infected patients: 96 week analysis of ARTEMIS. AIDS 2009, 23:1679-1688.
9. Madruga J., Berger D. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced. HIV-infected patients in TITAN: a randomized, controlled Phase III trial. Lancet 2007, 370:49-58.
10. Katlama C., Esposito R. Efficacy and safety of TMC 114/ritonavir in treatment-experienced HIV patients: 24 week results of POWER 1. AIDS 2007, 21:395-402.
11. Haubrich R., Berger D. Week 24 efficacy and safety of TMC 114/ritonavir in treatment-experienced HIV patients. AIDS 2007, 21:F11-F18.
12. Molina J, Cohen C. Safety and efficacy of darunavir (TMC 114) with low-dose ritonavir in treatment-experienced patients: 24 week results of POWER 3. J Acquir Immune Defic Syndr. 2007.(Epub ahead of print).
13. Clotet B., Bellos N. Efficacy and safety of darunavir-ritonavir at week 48 in treatment experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007, 369:1169-1178.
14. Sekar V, De Meyer S. Pharmacokinetic/pharmacodynamic (PK/PD) analyses of TMC 114 in the POWER 1 and POWER 2 trials in treatment-experienced HIV-infected patients. Presented at: 13th aconference on Retroviruses and opportunistic Infections; February 5-8, 2006; Denver, Colorado, USA. Abstract J-121.
15. Cahm P., Fourie J. ODIN: 48 week analysis of once versus twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS 2011, 25(7):929-939.